69 Recruiting Studies Using Osimertinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Osimertinib
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
📍 BC Cancer, Vancouver Centre — Vancouver, British Columbia
Lung Cancer Non-small Cell Stage IV
View Study & Checklist ➔Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
📍 Smilow Cancer Center/Yale-New Haven Hospital — New Haven, Connecticut
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
📍 Research Site — Orlando, Florida
Carcinoma
View Study & Checklist ➔Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Non-Small Cell Lung Cancer
View Study & Checklist ➔A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
📍 Scottsdale Healthcare /ID# 123761 — Scottsdale, Arizona
Advanced Solid Tumors Cancer
View Study & Checklist ➔Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
📍 Research Site — La Jolla, California
Carcinoma, Non-Small-Cell Lung
View Study & Checklist ➔HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
📍 UCLA — Santa Monica, California
Non-Small Cell Lung Cancer (NSCLC)
View Study & Checklist ➔Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
📍 Research Site — Duarte, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist ➔A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
📍 Research Site — Duarte, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
📍 UCSD Moores Cancer Center — La Jolla, California
Lung Cancer
View Study & Checklist ➔Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
📍 Research Site — La Jolla, California
Carcinoma
View Study & Checklist ➔A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
📍 Massachusetts General Hospital — Boston, Massachusetts
Non-small Cell Lung Cancer
View Study & Checklist ➔To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
📍 Research Site — La Jolla, California
Lung Cancer
View Study & Checklist ➔Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
📍 UCSF Medical Center-Mount Zion — San Francisco, California
Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist ➔Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lung Non-Small Cell Carcinoma
View Study & Checklist ➔A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
📍 Research Site — Silver Spring, Maryland
Non-small Cell Lung Cancer
View Study & Checklist ➔A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
📍 Research Site — Santa Rosa, California
Stage II-IIIB Non-small Cell Lung Carcinoma
View Study & Checklist ➔Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
📍 City of Hope Medical Center — Duarte, California
Non-small Cell Lung Cancer (NSCLC)
View Study & Checklist ➔Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
View Study & Checklist ➔Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
📍 Washington University School of Medicine — St Louis, Missouri
Metastatic Non Small Cell Lung Cancer
View Study & Checklist ➔A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
📍 Memorial Sloan Kettering Cancer Center — Basking Ridge, New Jersey
Lung Cancer
View Study & Checklist ➔A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
📍 Research Site — Anchorage, Alaska
Non-Small Cell Lung Cancer
View Study & Checklist ➔A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
📍 Research Site — Duarte, California
Non Small Cell Lung Cancer (Stage III)
View Study & Checklist ➔Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC
📍 Huntsman Cancer Institute — Salt Lake City, Utah
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
View Study & Checklist ➔Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
📍 Dana-Farber Cancer Institute /ID# 231209 — Boston, Massachusetts
Advanced Solid Tumors Cancer
View Study & Checklist ➔A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
📍 Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Solid Tumor, Adult
View Study & Checklist ➔A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
📍 UCLA Hematology/Oncology - Santa Monica — Los Angeles, California
Metastatic Non-Small Cell Lung Cancer
View Study & Checklist ➔Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
📍 Massachusetts General Hospital — Boston, Massachusetts
Advanced Solid Tumors Which Are cMET-dependent
View Study & Checklist ➔Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
📍 University of California, Irvine — Orange, California
Non-Small Cell Lung Cancer Metastatic
View Study & Checklist ➔Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
📍 Research Site — Duarte, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
📍 Los Angeles General Medical Center — Los Angeles, California
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
📍 Georgetown University — Washington D.C., District of Columbia
Non Small Cell Lung Cancer
View Study & Checklist ➔First in Human Study of AZD9592 in Solid Tumors
📍 Research Site — Duarte, California
Advanced Solid Tumours
View Study & Checklist ➔Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
📍 University of California, Davis — Davis, California
Stage I Non-Small Cell Lung Cancer
View Study & Checklist ➔A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
📍 Arizona Oncology Associates, PC - HAL — Goodyear, Arizona
Carcinoma, Non-Small-Cell Lung
View Study & Checklist ➔Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
📍 City of Hope Medical Center — Duarte, California
Advanced Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Osimertinib In EGFR Mutant Lung Cancer
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Carcinoma, Non-Small-Cell Lung
View Study & Checklist ➔A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
📍 Research Site — Bellflower, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
📍 Local Institution - 0212 — Beverly Hills, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
📍 Valkyrie Clinical Trials — Los Angeles, California
Carcinoma, Non-Small Cell Lung
View Study & Checklist ➔Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
📍 UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
Solid Tumor, Adult
View Study & Checklist ➔Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
📍 Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
Recurrent Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
📍 Cedars-Sinai Cancer at Beverly Hills (THO) — Beverly Hills, California
Non Small Cell Lung Cancer
View Study & Checklist ➔Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Advanced Lung Non-Small Cell Carcinoma
View Study & Checklist ➔A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
📍 Highlands Oncology Group - Springdale /ID# 277132 — Springdale, Arkansas
Non-Small Cell Lung Cancer
View Study & Checklist ➔Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
📍 University of Kentucky Chandler Medical Center — Lexington, Kentucky
Non-Small Cell Lung Cancer
View Study & Checklist ➔Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Locally Advanced Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
📍 Research Site — Fountain Valley, California
Non-small Cell Lung Cancer
View Study & Checklist ➔Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Lung Non-Small Cell Carcinoma
View Study & Checklist ➔A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
📍 BAPTIST ALLIANCE - MCI (Data Collection Only) — Miami, Florida
Non Small Cell Lung Cancer Metastatic
View Study & Checklist ➔A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
📍 University of Alabama at Birmingham — Birmingham, Alabama
Lung Cancer
View Study & Checklist ➔MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Advanced Lung Non-Small Cell Carcinoma
View Study & Checklist ➔A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
📍 Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
Non-Small Cell Lung Cancer
View Study & Checklist ➔Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
📍 Maryland Oncology Hematology — Calverton, Maryland
EGFR Mutation Positive Non-small Cell Lung Cancer
View Study & Checklist ➔Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
📍 Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
Small Cell Lung Cancer ( SCLC )
View Study & Checklist ➔Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
📍 UC Davis Cancer Center (Data Collection Only) — Sacramento, California
Metastatic Non-small Cell Lung Cancer
View Study & Checklist ➔A Study of DB-1310 in Advanced/Metastatic Solid Tumors
📍 University of California, Davis Comprehensive Cancer Center — Sacramento, California
Advanced Solid Tumor
View Study & Checklist ➔A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
📍 Research Site — Fayetteville, Arkansas
Metastatic Non-small Cell Lung Cancer
View Study & Checklist ➔Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
📍 City of Hope Medical Center — Duarte, California
Lung Non-Small Cell Carcinoma
View Study & Checklist ➔A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
📍 Ironwood Cancer and Research Centers - Chandler II /ID# 275443 — Chandler, Arizona
Non-Squamous Non-Small Cell Lung Cancer
View Study & Checklist ➔Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
📍 BC Cancer Agency — Vancouver, British Columbia
Non-Small Cell Lung Cancer
View Study & Checklist ➔Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
📍 University of Alabama at Birmingham — Birmingham, Alabama
Non Small Cell Lung Cancer
View Study & Checklist ➔Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
View Study & Checklist ➔